Precision-Engineered Synthetic Cell Mimic™ Controls. Reproducible, Comparable Data You Can Trust. Every Time.
Leave behind the unpredictability of biological cells and the limitations of polystyrene beads. Our cell mimics provide greater stability and accuracy across the board:
Our polymer-based cell mimics are fully customizable, engineered to replicate specific cellular characteristics for precise control in every assay.
TruCytes™ Biomarker Controls
Mimic and quantify specific cell types and their functions with customizable proteins.
ViaComp Cell Health Controls
Assess cell viability with controls for DNA intercalating and amine-reactive dyes.
SpectraComp Compensation Controls
Achieve superior compensation and unmixing controls, staining like real cells.
FlowCyte Calibration Controls
Set new standards for instrument calibration and traceability.
Slingshot Bio cell mimics consistently outperform traditional controls — such as those that come from blood specimens or solid-core plastic beads — across fluorescence, light scattering, and biomarker compatibility. No cell culture, no donor variability—just ready-to-use reliability.
Biological Controls
Polystyrene Beads
See how Slingshot and Cerba Research worked together to develop cell mimics for Ki-67, a critical protein in cancer research. With our mimics, Cerba validated assays with greater accuracy and reduced variability compared to live cells.
“We’ve integrated Slingshot cell mimics as crucial controls in several of our flow cytometry workflows. Whether in assessing cell viability or managing compensation and unmixing, these off-the-shelf controls seamlessly slot into our processes. This enhances our workflow efficiency without having to compromise on data quality and reliability.”
Dr. Veronica Nash | US Regional Head of Flow Cytometry
Cerba Research
See how we helped Prolocor design the ideal control for their platelet FcγRIIa precision diagnostic test that quantifies FcγRIIa on the surface of platelets to guide clinical decision making.
“Clinicians need better tools to guide decision making on the choice of antiplatelet therapy in coronary artery disease patients, particularly after coronary stenting. The Prolocor pFCG® test will be an important asset as we tailor antiplatelet therapies to balance thrombotic and bleeding risk.”
Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI | Professor of Medicine, Chief, Division of Cardiology, Director, Thrombosis Research Center
University of Florida, College of Medicine-Jacksonville.
See how we partnered with Fred Hutch CPF QC to engineer custom CD3 T cell mimics with varying percentages of expression of the common CAR transduction marker epidermal growth factor receptor (EGFR) to validate their CAR T cell flow cytometry assays.
“In our search for reliable controls for cell therapy assays, partnering with Slingshot has been a game-changer. Together, we addressed significant challenges by engineering custom CD3 T-cell mimics.”
Amina Kariminia, Ph.D. | Immunologist, Analytical Development Scientist
Fred Hutch Cancer Center
